drugset / Trial / NCT05334004
Lopinavir/Ritonavir in PLWH With High-Grade AIN
Phase 1
Recruiting
21 enrolled
University of Wisconsin, Madison
Wisconsin Partnership Program · collab
Non-randomizedSequentialOpen-labelPrevention
Summary
This study is being done to assess the safety of lopinavir/ritonavir in patients with PLWH with AIN. 30 participants will be recruited and can expect to be on active study for approximately 3 months and long term follow up for 40 weeks.
Timeline
- Start
- 2023-12-19
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 200 mg | Other |
| Subject | Lopinavir | Other / unclassified | 400 mg | Other |
| Subject | Lopinavir | Other / unclassified | 600 mg | Other |
| Subject | Ritonavir | Other / unclassified | 50 mg | Other |
| Subject | Ritonavir | Other / unclassified | 100 mg | Other |
| Subject | Ritonavir | Other / unclassified | 150 mg | Other |